Posted by Michael Wonder on 01 Feb 2022
Byannli authorised in Britain for schizophrenia treatment
1 February 2022 - Market authorisation for twice yearly schizophrenia treatment which offers patients much-needed medication continuity
The Medicines and Healthcare products Regulatory Agency has granted marketing authorisation in Britain for the long-acting atypical antipsychotic therapy Byannli–the six monthly paliperidone palmitate for the maintenance treatment of schizophrenia in adult patients.
